NMTCHIGH SIGNALOPERATIONAL10-K

NMTC has substantially narrowed its losses while advancing key product launches, including a December 2025 limited market release of its OneRF TN Ablation System and expanded commercialization through its Zimmer partnership.

The company appears to be transitioning from pure development to commercialization phase, evidenced by specific product launches and a more focused business description that emphasizes commercialized products rather than broad development goals. The meaningful improvement in financial metrics across revenue, operating performance, and cash flow suggests the business model is gaining traction, though the company remains loss-making as it scales operations.

Comparing 2025-12-17 vs 2024-12-17View on EDGAR →
FINANCIAL ANALYSIS

NMTC demonstrated substantially improved financial performance with operating losses, net losses, and operating cash flow deficits all meaningfully reduced year-over-year. The company also strengthened its balance sheet by reducing total debt by over half and cutting total liabilities by 18.4%, while inventory declined modestly. The overall financial picture suggests a company successfully transitioning toward profitability while maintaining disciplined cost management and reducing financial leverage.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-78.2%
$14K$3K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Operating Cash Flow
Cash Flow
+74.2%
-$11.0M-$2.8M

Operating cash flow surged 74.2% — exceptional cash generation, highest quality earnings signal.

Net Income
P&L
+70.7%
-$12.3M-$3.6M

Net income grew 70.7% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+64.4%
-$11.9M-$4.2M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Total Debt
Balance Sheet
-53.8%
$120K$55K

Debt reduced 53.8% — deleveraging strengthens balance sheet and reduces financial risk.

Capital Expenditure
Cash Flow
-32%
$120K$82K

Capex reduced 32% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Liabilities
Balance Sheet
-18.4%
$4.5M$3.7M

Liabilities reduced 18.4% — deleveraging improves balance sheet strength and financial flexibility.

Inventory
Balance Sheet
-15.5%
$2.6M$2.2M

Inventory reduced 15.5% — lean inventory management or demand outpacing supply.

LANGUAGE CHANGES
NEW — 2025-12-17
PRIOR — 2024-12-17
ADDED
The number of outstanding shares of the registrant s common stock as of December 12, 2025 was 50,413,148 .
Forward-looking statements include statements about: our ability to successfully commercialize our technology in the United States; the results of our development and distribution relationship with Zimmer, Inc.
with a license to commercialize and distribute the Evo Cortical, Evo sEEG, and OneRF Brain Ablation System in the brain.
We initiated a limited market release of the OneRF TN Ablation System in December 2025.
Products We are focused on developing thin film electrode technology for a variety of recording and therapeutic applications.
+7 more — sign up free →
REMOVED
The number of outstanding shares of the registrant s common stock as of December 13, 2024 was 30,841,830 .
We are developing and commercializing thin film electrode technology for continuous electroencephalogram ( cEEG ) and stereoelectrocencephalography ( sEEG ), spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, Parkinson s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other pain-related neurological disorders.
The Company is also developing the capability to use its sEEG electrode technology to deliver drugs or gene therapy while being able to record brain activity before, during, and after delivery.
Additionally, we are investigating the potential applications of its technology associated with artificial intelligence.
( Zimmer ) providing Zimmer with a license to commercialize and distribute these three products in the brain.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →